Top Urinary Tract Infection Treatment Companies in 2025
12 May, 2025

Overview of the Urinary Tract Infection (UTI) Treatment Market

Urinary Tract Infection (UTI) treatment is the medical management for the removal of bacterial infections in the urinary system, which involves the bladder, kidneys, ureters, and urethra. UTIs are usually caused by bacteria and present with frequent urination, painful urination, lower abdominal pain, and sometimes fever.

The most common treatment for UTIs is antibiotics, which work by attacking and eliminating the bacteria that cause infection. The treatment can be oral antibiotics for a straightforward case or intravenous antibiotics for a more serious case.

Aside from antibiotics, pain medications or anti-inflammatory drugs are sometimes given to treat pain. In chronic or frequent UTIs, physicians might also suggest additional diagnostic procedures to find underlying causes or prevention treatments. Women are more likely to get UTIs, but they can be experienced by anyone, and immediate treatment must be sought in order to avoid complications, such as kidney injury or infection spreading.

The worldwide urinary tract infection (UTI) therapy market is expected to grow from US$9.13 billion in 2024 to US$11.64 billion in 2033 at a compound annual growth rate (CAGR) of 2.74% between 2025 and 2033. The growth is driven by the increasing prevalence of UTIs among women and older people, as well as ongoing innovation in antimicrobial therapy.

India Urinary Tract Infection (UTI) treatment market

Treatment of Urinary Tract Infection (UTI) is through antibiotics to clear bacterial infections in the urinary organs, including the kidneys, bladder, ureters, and urethra. Nitrofurantoin, fosfomycin, and ciprofloxacin are common antibiotics, with intravenous antibiotics for severe infections. Effective management of UTI in India is important to avoid complications such as kidney infection and sepsis. UTIs are common because of conditions such as high diabetes prevalence and unsanitary conditions, particularly in women, the elderly, and immunocompromised patients. Probiotics, fluid intake, and cranberry supplements are becoming increasingly popular for prevention. As healthcare awareness increases, India is seeing an uptick in rapid diagnostic testing and telemedicine consultations, enhancing UTI detection and treatment efficiency in urban and rural settings. The India urinary tract infection treatment market is expected to reach US$ 517.78 million in 2033, from US$ 384.85 million in 2024, and will grow with a compound annual growth rate of 3.35% from 2025 to 2033.

Asia Pacific Urinary Tract Infection (UTI) treatment market

The treatment of urinary tract infection (UTI) in the Asia Pacific region includes mainly the employment of antibiotics in order to rid the urinary tract, such as the kidneys, bladder, ureters, and urethra, of the bacterial infection. Usual antibiotics used include nitrofurantoin, fosfomycin, and ciprofloxacin, with intravenous antibiotics for severe infections. UTIs are of major concern in Asia Pacific owing to high healthcare awareness, high rates of diabetes, and low access to sanitation in certain regions. Women, the elderly, and immunocompromised individuals are especially at risk.

Aside from antibiotics, treatments can involve painkillers, hydration, and lifestyle modification. Probiotics, cranberry, and a higher intake of water are becoming increasingly popular as preventive strategies. Prompt treatment and early diagnosis are crucial in order to avoid complications like kidney injury or sepsis. With advancements in healthcare systems, there is increasing utilization of rapid tests for diagnosis and telemedicine, especially in remote locations, for better and faster management of UTI. The Asia Pacific Urinary Tract Infection (UTI) treatment market is expected to expand from US$ 3.13 billion in 2024 to US$ 4.10 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 3.05% during the period from 2025 to 2033.

Discover key trends, growth opportunities, and major challenges shaping the Global Urinary Tract Infection Treatment Industry in Renub Research’s latest in-depth market report. Download your free sample now

Top urinary tract infection treatment companies

AstraZeneca

Founding: 1999

Head Office: United Kingdom

Website: www.astrazeneca.com

AstraZeneca Plc is a biopharmaceutical firm engaged in the discovery, development, and marketing of prescription drugs. Its products comprise biologics, pharmaceuticals, and vaccines for therapeutic categories like respiratory, cardiovascular, metabolic, oncology, autoimmune, infectious, and neurological diseases. AstraZeneca distributes its products worldwide through local subsidiaries, distributors, and representative offices to primary care and specialty care physicians.

Bayer AG

Founding: 1863

Head Office: Germany

Website: www.bayer.com

Bayer AG is a multinational corporation involved in the discovery, development, manufacturing, and marketing of health care and agricultural products. It has medicines for cardiovascular diseases, cancer, women's health, hematology, ophthalmology, and other conditions. Bayer also makes new molecules and technologies for medical and agricultural use. It has prescription medications, specialty drugs, OTC medicines, diagnostic imaging devices, seeds, crop protection products, and pest control products in its portfolio. The firm sells its products via pharmacies, wholesalers, hospitals, and retailers and has presence in Asia-Pacific, Europe, the Americas, Africa, and the Middle East.

GlaxoSmithKline PLC

Founding: 2000

Headquarter: United Kingdom

Website: www.gsk.com

GSK plc is a global health organization involved in the development, production, and sale of general and specialty medicines and vaccines. It offers HIV and respiratory diseases, cancer, immuno-inflammatory diseases, infections, CNS disorders, cardiovascular, metabolic, and rare disease treatments. GSK also provides over-the-counter medications for pain, oral and skin health, nutrition, and gastrointestinal conditions. Its vaccine portfolio addresses conditions like hepatitis, HPV, measles, meningitis, and whooping cough. GSK sells its products worldwide through wholesalers, pharmacies, hospitals, and healthcare practitioners.

Johnson & Johnson

Founded: 1886

Headquarters: United States of America

Website: www.jnj.com

Johnson & Johnson (J&J) is a multinational healthcare corporation engaged in the research, development, production, and marketing of innovative medicines and medical devices. Through its subsidiaries, J&J markets pharmaceutical products aimed at immune disorders, cancer, neurological diseases, infectious diseases, and cardiovascular and metabolic diseases. The company also offers medical devices utilized in cardiovascular, orthopedic, neurovascular treatment, general surgery, and vision care. J&J sells its products to hospitals, healthcare professionals, wholesalers, and retailers. Through manufacturing facilities in the US, Europe, Asia-Pacific, Africa, the Western Hemisphere (except the US), and Latin America, J&J has a robust global presence.

Novartis AG

Founding: 1996

Head office: Switzerland

Website: www.novartis.com

Novartis AG is a multinational pharmaceutical company dedicated to research, development, production, and marketing of innovative drugs. It has products in key therapeutic areas such as cardiovascular, renal, metabolic, immunology, ophthalmology, respiratory, neuroscience, oncology, and global health. Novartis sells its drugs under popular brands such as Entresto, Cosentyx, Kesimpta, Kisqali, and Tasigna. The customer base of Novartis consists of pharmacists, healthcare providers, hospitals, insurers, and government health systems. Manufacturing sites of the company are present in the US, Switzerland, Austria, Slovenia, China, France, and Italy.

Pfizer

Formation: 1849

Headquarters: United States of America

Website: www.pfizer.com

Pfizer Inc. is a research-based biopharmaceutical corporation engaged in discovering, developing, manufacturing, marketing, and distributing medications and vaccines. Its products span therapeutic categories such as oncology, anti-infectives, cardiovascular diseases, diabetes, obesity, immunology, inflammation, rare diseases, and bacterial infections. Pfizer's medications are utilized by hospitals, clinics, healthcare professionals, and pharmacies to treat a range of medical conditions. The firm sells its products worldwide via wholesalers, retailers, and government institutions, and its major brands include Zavzpret, Abrysvo, Inflectra, Genotropin, Octagam, and Bosulif. Pfizer has manufacturing plants in nations such as the US, India, Germany, Italy, Ireland, Belgium, Japan, and Singapore.

Merck & Co. Inc

Founding: 1891

Headquarters: United States of America

Website: www.merck.com

Merck & Co., Inc. is a worldwide biopharmaceutical leader that focuses on the discovery, development, manufacture, and marketing of prescription medications, biologic therapies, vaccines, and animal health products. Its human health portfolio targets therapeutic areas including cardiovascular disease, cancer, immune disorders, infectious and respiratory diseases, and diabetes. For the animal health business, Merck provides vaccines and therapeutics for poultry, livestock, aquaculture, and pets. The firm sells its human pharmaceuticals via wholesalers, hospitals, retailers, government institutions, and healthcare practitioners, while veterinary health products are sold to vets, distributors, and animal breeders. Merck has subsidiaries in the Americas, Europe, Asia Pacific, the Middle East, Africa, and Latin America.

Dr Reddy's Laboratories Ltd

Establishment: 1984

Headquarters: India

Website: https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd is an international pharmaceutical firm that is involved in the production and sale of prescription drugs, over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), and intermediates. Its generic portfolio comprises generics, branded generics, biosimilars, and OTC drugs applied across therapeutic segments including gastroenterology, oncology, cardiovascular care, diabetes, dermatology, and pain relief. The organization is committed to delivering affordable and accessible healthcare options globally. Dr. Reddy's also emphasizes research with an innovative pipeline of New Chemical Entities (NCEs) for metabolic disorders, infections, pain, and inflammation. It has a robust global presence in the US, Europe, Latin America, and Asia.

Bristol-Myers Squibb Company

Founding: 1887

Headquarters: United States of America

Website: www.bms.com

Bristol-Myers Squibb Co (BMS) is a biopharmaceutical firm that concentrates on the discovery, development, production, and marketing of novel drugs. Its pipeline covers core therapeutic areas of oncology, hematology, immunology, cardiovascular, and neuroscience. BMS partners with third parties by entering into partnership agreements, license arrangements, and joint ventures in order to accelerate drug development. BMS sells drugs under its brand names such as Opdivo, Reblozyl, Krazati, Sprycel, and Sotyktu. It distributes through wholesalers, specialty pharmacies, hospitals, clinics, and government entities. BMS has manufacturing units in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands.